PHOTOCURE ASA (PHO.OL) Fundamental Analysis & Valuation

OSL:PHO • NO0010000045

Current stock price

59.7 NOK
+0.4 (+0.67%)
Last:

This PHO.OL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. PHO.OL Profitability Analysis

1.1 Basic Checks

  • PHO had negative earnings in the past year.
  • PHO had a positive operating cash flow in the past year.
  • PHO had negative earnings in 4 of the past 5 years.
  • PHO had a positive operating cash flow in 4 of the past 5 years.
PHO.OL Yearly Net Income VS EBIT VS OCF VS FCFPHO.OL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50M -50M -100M -150M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -0.21%, PHO is doing worse than 63.46% of the companies in the same industry.
  • PHO has a worse Return On Equity (-0.31%) than 63.46% of its industry peers.
Industry RankSector Rank
ROA -0.21%
ROE -0.31%
ROIC N/A
ROA(3y)-0.18%
ROA(5y)-2.89%
ROE(3y)-0.26%
ROE(5y)-4.49%
ROIC(3y)N/A
ROIC(5y)N/A
PHO.OL Yearly ROA, ROE, ROICPHO.OL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 -10 -20

1.3 Margins

  • The Gross Margin of PHO (92.11%) is better than 96.15% of its industry peers.
  • In the last couple of years the Gross Margin of PHO has remained more or less at the same level.
  • The Profit Margin and Operating Margin are not available for PHO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 92.12%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.75%
GM growth 5Y-0.14%
PHO.OL Yearly Profit, Operating, Gross MarginsPHO.OL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 60 80

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. PHO.OL Health Analysis

2.1 Basic Checks

  • PHO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PHO has less shares outstanding than it did 1 year ago.
  • PHO has less shares outstanding than it did 5 years ago.
  • PHO has a worse debt/assets ratio than last year.
PHO.OL Yearly Shares OutstandingPHO.OL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M 25M
PHO.OL Yearly Total Debt VS Total AssetsPHO.OL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M

2.2 Solvency

  • An Altman-Z score of 5.53 indicates that PHO is not in any danger for bankruptcy at the moment.
  • With an excellent Altman-Z score value of 5.53, PHO belongs to the best of the industry, outperforming 82.69% of the companies in the same industry.
  • PHO has a debt to FCF ratio of 19.05. This is a negative value and a sign of low solvency as PHO would need 19.05 years to pay back of all of its debts.
  • Looking at the Debt to FCF ratio, with a value of 19.05, PHO is doing worse than 71.15% of the companies in the same industry.
  • PHO has a Debt/Equity ratio of 0.21. This is a healthy value indicating a solid balance between debt and equity.
  • With a decent Debt to Equity ratio value of 0.21, PHO is doing good in the industry, outperforming 71.15% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 19.05
Altman-Z 5.53
ROIC/WACCN/A
WACC8.39%
PHO.OL Yearly LT Debt VS Equity VS FCFPHO.OL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • PHO has a Current Ratio of 3.64. This indicates that PHO is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 3.64, PHO belongs to the top of the industry, outperforming 94.23% of the companies in the same industry.
  • A Quick Ratio of 3.22 indicates that PHO has no problem at all paying its short term obligations.
  • PHO's Quick ratio of 3.22 is amongst the best of the industry. PHO outperforms 94.23% of its industry peers.
Industry RankSector Rank
Current Ratio 3.64
Quick Ratio 3.22
PHO.OL Yearly Current Assets VS Current LiabilitesPHO.OL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. PHO.OL Growth Analysis

3.1 Past

  • PHO shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 54.03%, which is quite impressive.
  • Looking at the last year, PHO shows a small growth in Revenue. The Revenue has grown by 1.37% in the last year.
  • PHO shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.74% yearly.
EPS 1Y (TTM)54.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.32%
Revenue 1Y (TTM)1.37%
Revenue growth 3Y10.65%
Revenue growth 5Y15.74%
Sales Q2Q%5.45%

3.2 Future

  • PHO is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -8.63% yearly.
  • PHO is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 16.26% yearly.
EPS Next Y-74.23%
EPS Next 2Y25.27%
EPS Next 3Y-8.63%
EPS Next 5YN/A
Revenue Next Year14.93%
Revenue Next 2Y11.61%
Revenue Next 3Y9.72%
Revenue Next 5Y16.26%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
PHO.OL Yearly Revenue VS EstimatesPHO.OL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 200M 400M 600M 800M 1B
PHO.OL Yearly EPS VS EstimatesPHO.OL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 1 -1 2 -2

More info and screens

Find the best growth stocksShow best growing peers

0

4. PHO.OL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for PHO. In the last year negative earnings were reported.
  • With a Price/Forward Earnings ratio of 157.62, PHO can be considered very expensive at the moment.
  • Based on the Price/Forward Earnings ratio, PHO is valued a bit more expensive than the industry average as 69.23% of the companies are valued more cheaply.
  • When comparing the Price/Forward Earnings ratio of PHO to the average of the S&P500 Index (22.84), we can say PHO is valued expensively.
Industry RankSector Rank
PE N/A
Fwd PE 157.62
PHO.OL Price Earnings VS Forward Price EarningsPHO.OL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 -200 -400 -600 -800

4.2 Price Multiples

  • 67.31% of the companies in the same industry are cheaper than PHO, based on the Enterprise Value to EBITDA ratio.
  • 71.15% of the companies in the same industry are cheaper than PHO, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 308.22
EV/EBITDA 51.53
PHO.OL Per share dataPHO.OL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • PHO's earnings are expected to decrease with -8.63% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.27%
EPS Next 3Y-8.63%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. PHO.OL Dividend Analysis

5.1 Amount

  • PHO does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHO.OL Fundamentals: All Metrics, Ratios and Statistics

PHOTOCURE ASA

OSL:PHO (4/1/2026, 7:00:00 PM)

59.7

+0.4 (+0.67%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-18
Earnings (Next)05-07
Inst Owners41.67%
Inst Owner ChangeN/A
Ins Owners2.81%
Ins Owner ChangeN/A
Market Cap1.62B
Revenue(TTM)532.58M
Net Income(TTM)-1.52M
Analysts80
Price Target81.6 (36.68%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)-1.02%
Min Revenue beat(2)-2.51%
Max Revenue beat(2)0.47%
Revenue beat(4)2
Avg Revenue beat(4)-1.3%
Min Revenue beat(4)-5.24%
Max Revenue beat(4)2.07%
Revenue beat(8)4
Avg Revenue beat(8)-1.81%
Revenue beat(12)6
Avg Revenue beat(12)-2.3%
Revenue beat(16)8
Avg Revenue beat(16)-2.79%
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-61.6%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)1.65%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 157.62
P/S 3.04
P/FCF 308.22
P/OCF 62.37
P/B 3.34
P/tB 6.2
EV/EBITDA 51.53
EPS(TTM)-0.06
EYN/A
EPS(NY)0.38
Fwd EY0.63%
FCF(TTM)0.19
FCFY0.32%
OCF(TTM)0.96
OCFY1.6%
SpS19.64
BVpS17.86
TBVpS9.63
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -0.21%
ROE -0.31%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 92.12%
FCFM 0.99%
ROA(3y)-0.18%
ROA(5y)-2.89%
ROE(3y)-0.26%
ROE(5y)-4.49%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.75%
GM growth 5Y-0.14%
F-Score4
Asset Turnover0.75
Health
Industry RankSector Rank
Debt/Equity 0.21
Debt/FCF 19.05
Debt/EBITDA 3.48
Cap/Depr 70.25%
Cap/Sales 3.89%
Interest Coverage N/A
Cash Conversion 90.36%
Profit Quality N/A
Current Ratio 3.64
Quick Ratio 3.22
Altman-Z 5.53
F-Score4
WACC8.39%
ROIC/WACCN/A
Cap/Depr(3y)51.48%
Cap/Depr(5y)36.92%
Cap/Sales(3y)2.84%
Cap/Sales(5y)2.09%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)54.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-88.32%
EPS Next Y-74.23%
EPS Next 2Y25.27%
EPS Next 3Y-8.63%
EPS Next 5YN/A
Revenue 1Y (TTM)1.37%
Revenue growth 3Y10.65%
Revenue growth 5Y15.74%
Sales Q2Q%5.45%
Revenue Next Year14.93%
Revenue Next 2Y11.61%
Revenue Next 3Y9.72%
Revenue Next 5Y16.26%
EBIT growth 1Y-103.65%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year48.59%
EBIT Next 3Y24.55%
EBIT Next 5YN/A
FCF growth 1Y-91.96%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-66.18%
OCF growth 3YN/A
OCF growth 5Y10.74%

PHOTOCURE ASA / PHO.OL Fundamental Analysis FAQ

What is the fundamental rating for PHO stock?

ChartMill assigns a fundamental rating of 3 / 10 to PHO.OL.


What is the valuation status of PHOTOCURE ASA (PHO.OL) stock?

ChartMill assigns a valuation rating of 0 / 10 to PHOTOCURE ASA (PHO.OL). This can be considered as Overvalued.


What is the profitability of PHO stock?

PHOTOCURE ASA (PHO.OL) has a profitability rating of 2 / 10.


What is the earnings growth outlook for PHOTOCURE ASA?

The Earnings per Share (EPS) of PHOTOCURE ASA (PHO.OL) is expected to decline by -74.23% in the next year.